aKTIV8 is an AI-powered business development (BD) intelligence platform for the life sciences industry. It tracks 35,000+ biotech, biopharma, and pharmaceutical companies and surfaces signals — clinical milestones, FDA catalysts, funding rounds, partnerships, and news — to help BD professionals identify and act on opportunities faster.
aKTIV8 is designed for BD professionals, licensing managers, strategic analysts, and executives at pharmaceutical, biotech, and biopharma companies. It is also used by CROs, CDMOs, venture capital firms, investment banks, and life sciences consultancies.
Most pharma databases are static repositories. aKTIV8 is a live intelligence platform — it continuously processes news, regulatory filings, and clinical data to surface timely signals rather than just providing searchable records. The AI layer (HAKASE) also synthesises data into actionable insights, BD reports, and outreach materials, which generic databases cannot do.
HAKASE is aKTIV8's AI intelligence engine. It answers BD questions, generates company reports, drafts outreach emails, and writes the daily intelligence brief — all grounded strictly in platform data. It does not generate hallucinated facts. HAKASE is publicly accessible at https://aktiv8.io/hakase.
aKTIV8 aggregates data from BioPharmCatalyst (catalysts and company registry), ClinicalTrials.gov, 20+ industry RSS news feeds (FierceBiotech, STAT News, Endpoints News, BioSpace, GlobeNewswire, and others), NIH Reporter (grants), bioRxiv (preprints), and Hunter.io (contact enrichment). Data is updated every 6–24 hours depending on source.
The news scanner runs every 6 hours, pulling from 20+ RSS feeds. The public news page at /news shows articles from the last 90 days, sorted newest first. On the production platform, articles are typically less than 6 hours old when they appear.
Yes. The public news feed at https://aktiv8.io/news is accessible without a login. The Daily Brief archive at https://aktiv8.io/brief/[date] is also publicly accessible. HAKASE has a public-facing demo at https://aktiv8.io/hakase. Full platform access requires an account.
The Daily Brief is an AI-written intelligence digest generated each morning at 7:00 AM Gulf time (3:00 AM UTC). It covers the day's most significant catalysts, funding events, regulatory decisions, and partnerships, with a HAKASE Analysis section providing contextual narrative. It is delivered by email to subscribers and accessible at https://aktiv8.io/brief/[YYYY-MM-DD].
Yes. aKTIV8 has dedicated intelligence modules for the Middle East & Africa (MEA) and India markets, with regional trade feeds, local news sources, and country-specific company coverage. Geographic access controls allow users to be scoped to specific markets.
Visit https://aktiv8.io/news or https://aktiv8.io/ and click "Subscribe to the Daily Brief." You will receive the brief by email each morning.
Yes. HAKASE can draft personalised BD outreach emails for any company in the platform. The emails are grounded in the company's actual profile — pipeline assets, recent milestones, clinical stage — rather than generic templates. This is available to authenticated platform users.
aKTIV8 covers all therapeutic areas tracked by the life sciences industry: oncology, rare diseases, neurology, immunology, infectious diseases, cardiovascular, metabolic disorders, ophthalmology, and more. The platform does not specialise in a single therapeutic area — it provides broad coverage across the full pharma/biotech landscape.
See https://aktiv8.io/pricing for current pricing. Subscription plans are available for individual users and teams. Enterprise pricing is available for organisations requiring geo-scoped access, multi-user licences, or custom integrations.
Visit https://aktiv8.io/ and use the "Book a demo" button, or subscribe to the Daily Brief to get in touch with the team.